Buy Dr Reddy's, Cipla, NIIT Tech, Tata Motors: Sanjiv Bhasin

Sanjiv Bhasin, executive vice president, markets & corporate affairs at IIFL says domestic markets have been able to delink themselves from weak global cues. (Watch)

Stock Talk

Dr Reddy's Lab: Despite the run up, it may still offer a bit of upside; quarterly numbers have shown growth.

Cipla: The stock has seen a downside after the results. Cipla's model is such that it keeps innovating and with certain drug approvals having come through in Europe, sales will start to kick in.

Tata Elxsi: The stock has outperformed, so investors should book profits now. All the way from Rs 1,100, we have been recommending profit booking.

NIIT Tech: Bullish on the stock. Any decline is an opportunity to get into the stock.

Tata Motors: At Rs 350, it is a buy.  All the negatives have been priced in including China slowdown and JLR.  The commercial vehicle (CV) segment is picking up and CV will be an outperformer in the domestic market.